Online Education | Neuropsychotropic Drug Therapy 2017 - Decoding Psychotropic Black Box Warnings
This module illuminates the history and current trends in black box warnings on psychotropic medications, with a focus on new data and controversies surrounding the potential adverse effects of carbamazepine and varenicline.
Jennifer Jepsen, PharmD, BCPS
Clinical Pharmacist, Pharmacy Department, Harborview Medical Center, Seattle
Comments and Reviews
"After hearing this talk, I will consider genetic testing before prescribing carbamazepine."
Nurse practitioners, clinical nurse specialists, nurses, pharmacists and other interested healthcare professionals.
Objectives for Learning Outcomes
At the conclusion of this activity, participants will be better able to:
- Revisit historical data that led to FDA Black Box labeling regarding antidepressants and suicidality.
- Review changes in antidepressant prescribing and rates of suicide attempts following antidepressant Black Box labeling.
- Summarize current data and controversy regarding antidepressant use and risk for increased suicidality.
- Describe HLA-B*1502 and identify patients that may benefit from genetic screening before use of carbamazepine.
- Outline data from the EAGLES study and impetus for reversal of labeling surrounding the adverse neuropsychotropic effects of varenicline.
- 1.05 Contact hours
- 1.05 Pharmacology hours at the advanced practice level